Searched for
SEMAGLUTIDE COMMERCIALISATION INDIA
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- Anthem BioSciences shares jump 4% as Citi initiates with Buy rating. Check target, upside potentialShares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...
- Emcure cuts semaglutide injection price by average 47%The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...
- Emcure slashes prices of weight management drug Poviztra by up to 55%Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- We need to quickly get OzempickyAffordable semaglutide generics are coming to India. This drug helps with diabetes and weight loss. Millions need it for health issues. How...
- Mankind Pharma targets early Semaglutide launchMankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankin...
- Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market shareNovo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...
- Abbott signs pact with Novo Nordisk to offer semaglutideSemaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic d...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in IndiaShares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...
- Eris Lifesciences partners Natco to commercialise semaglutideEris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes ...
- Emcure Pharma launches weight loss drug Poviztra in IndiaEmcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, becoming the first Indian company to exclusively dis...
- Novo, Emcure to launch weight-loss drug under new brand in IndiaIn June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...
- Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in IndiaNovo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...
- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
- Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO saysBiocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic ...
- Zydus working on single pen device for adjustable Semaglutide dosesZydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both d...
Load More
